AP3699A - 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment - Google Patents

2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

Info

Publication number
AP3699A
AP3699A AP2013006767A AP2013006767A AP3699A AP 3699 A AP3699 A AP 3699A AP 2013006767 A AP2013006767 A AP 2013006767A AP 2013006767 A AP2013006767 A AP 2013006767A AP 3699 A AP3699 A AP 3699A
Authority
AP
ARIPO
Prior art keywords
nucleoside analogs
fluoro substituted
antiviral treatment
substituted carba
carba
Prior art date
Application number
AP2013006767A
Other versions
AP2013006767A0 (en
Inventor
Aesop Cho
Choung Kim
Adrian Ray
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2013006767A0 publication Critical patent/AP2013006767A0/en
Application granted granted Critical
Publication of AP3699A publication Critical patent/AP3699A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2013006767A 2010-09-20 2011-03-22 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment AP3699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
PCT/US2011/029441 WO2012039791A1 (en) 2010-09-20 2011-03-22 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (2)

Publication Number Publication Date
AP2013006767A0 AP2013006767A0 (en) 2013-03-31
AP3699A true AP3699A (en) 2016-05-31

Family

ID=47748238

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006767A AP3699A (en) 2010-09-20 2011-03-22 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

Country Status (22)

Country Link
EP (1) EP2619206A1 (en)
JP (4) JP2013538230A (en)
KR (1) KR101879887B1 (en)
CN (1) CN103108876A (en)
AP (1) AP3699A (en)
AU (1) AU2011306066B2 (en)
BR (1) BR112013008017A2 (en)
CA (1) CA2807496C (en)
CL (1) CL2013000727A1 (en)
CO (1) CO6680669A2 (en)
CR (1) CR20130172A (en)
EA (1) EA026523B1 (en)
EC (1) ECSP13012560A (en)
IL (1) IL225221A0 (en)
MA (1) MA34593B1 (en)
MX (1) MX2013003179A (en)
NZ (1) NZ608070A (en)
PE (3) PE20230684A1 (en)
PH (1) PH12013500311B1 (en)
SG (1) SG188223A1 (en)
WO (1) WO2012039791A1 (en)
ZA (1) ZA201301042B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009240630B2 (en) 2008-04-23 2013-07-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
TWI483950B (en) 2009-09-21 2015-05-11 Gilead Sciences Inc Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
WO2012087596A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
AR088441A1 (en) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
UA119050C2 (en) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. PYROL [1.2-f] [1.2.4] TRIASINES USED FOR TREATMENT OF RESPIRATORY-SYNCITAL VIRAL INFECTIONS
TWI678369B (en) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
CN104230985B (en) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 Preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate
TWI740546B (en) 2014-10-29 2021-09-21 美商基利科學股份有限公司 Methods for the preparation of ribosides
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
SG10202109869XA (en) 2015-09-16 2021-10-28 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
CN110869028B (en) 2017-03-14 2023-01-20 吉利德科学公司 Method of treating feline coronavirus infection
ES2938859T3 (en) 2017-05-01 2023-04-17 Gilead Sciences Inc A crystalline form of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4 ]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
FI3706762T3 (en) 2017-12-07 2024-12-13 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
CN118662520A (en) 2020-01-27 2024-09-20 吉利德科学公司 Methods for treating SARS CoV-2 infection
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
HUE067491T2 (en) * 2020-08-27 2024-10-28 Gilead Sciences Inc Compounds and methods for treatment of viral infections
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
JP2025512935A (en) 2022-04-08 2025-04-22 シャイ・セラピューティクス・エルエルシー Compounds that interact with RAS superfamily proteins for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases
JP2025514335A (en) * 2022-04-25 2025-05-02 北京沐華生物科技有限責任公司 Nucleoside drugs and their use for treating or preventing coronavirus infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057287A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2006065335A2 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2009132123A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
DE69129650T2 (en) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Precursor of phosphonates
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (en) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
JP2003523978A (en) 2000-02-18 2003-08-12 シャイアー・バイオケム・インコーポレイテッド Methods for treating or preventing FLAVIVIRUS infection using nucleoside analogs
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
ATE491459T1 (en) 2000-10-18 2011-01-15 Pharmasset Inc MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRUS INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
US20040006002A1 (en) 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
CN100503628C (en) * 2003-05-30 2009-06-24 法莫赛特股份有限公司 Modified fluorinated nucleoside analogues
BRPI0515279A (en) 2004-09-14 2008-07-15 Pharmasset Inc preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101043893A (en) * 2004-10-21 2007-09-26 默克公司 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
JP5116687B2 (en) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008141079A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PE20161067A1 (en) * 2009-02-10 2016-10-23 Gilead Sciences Inc CARBA-NUCLEOSIDIC ANALOGS FOR ANTIVIRAL TREATMENT
BR122021021135B1 (en) * 2009-09-21 2022-08-30 Gilead Sciences, Inc 2-FLUORINE SUBSTITUTED CARBA-NUCLEOSIDE ANALOG COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF CARBONUCLEOSID 2'-FLUORINE SUBSTITUTED ANALOG COMPOUNDS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057287A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2006065335A2 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2009132123A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment

Also Published As

Publication number Publication date
PE20230684A1 (en) 2023-04-21
CR20130172A (en) 2013-05-29
KR20130110168A (en) 2013-10-08
CA2807496C (en) 2019-01-22
AU2011306066A1 (en) 2013-02-28
CL2013000727A1 (en) 2013-08-23
PE20131165A1 (en) 2013-10-14
AU2011306066B2 (en) 2015-01-29
NZ608070A (en) 2015-11-27
JP2017119726A (en) 2017-07-06
EP2619206A1 (en) 2013-07-31
EA201390141A1 (en) 2013-09-30
EA026523B1 (en) 2017-04-28
MA34593B1 (en) 2013-10-02
JP2013538230A (en) 2013-10-10
CA2807496A1 (en) 2012-03-29
JP6475280B2 (en) 2019-02-27
MX2013003179A (en) 2013-04-24
CO6680669A2 (en) 2013-05-31
PE20171624A1 (en) 2017-11-02
WO2012039791A1 (en) 2012-03-29
IL225221A0 (en) 2013-06-27
AP2013006767A0 (en) 2013-03-31
BR112013008017A2 (en) 2016-06-14
ZA201301042B (en) 2014-07-30
PH12013500311A1 (en) 2013-04-22
ECSP13012560A (en) 2013-06-28
KR101879887B1 (en) 2018-07-18
JP2016074732A (en) 2016-05-12
SG188223A1 (en) 2013-04-30
PH12013500311B1 (en) 2017-11-08
CN103108876A (en) 2013-05-15
JP2019014726A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
AP3699A (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
IL248110A0 (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
HUS2000055I1 (en) 1' -substituted carba-nucleoside analogs for antiviral treatment
IL256397A (en) 2'- substituted carba-nucleoside analogs for antiviral treatment
SI2576534T1 (en) 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
AP2922A (en) Carbra-nucleoside analogs for antiviral treatment
IL228680A0 (en) 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
IL226004A0 (en) Novel antiviral compounds
AP2013006824A0 (en) Substituted nucleotide analogs
HK1181678A (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
HK1182103A (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2627655A4 (en) Therapeutic 5,6,5-tricyclic analogs
GB201004879D0 (en) 69 TheGame
GB201001204D0 (en) Novel antiviral compounds
GB201113678D0 (en) "Data-Tank"
TH0901001785B (en) 1'-substituted carba-nucleoside analogs for antiviral therapy
GB201110470D0 (en) 22+(Blackjack)